NCT01501630View on ClinicalTrials.gov

Role of PET/CT With Fluorine-18 Tracers of Bone Metastases in Prostate Cancer

CompletedOBSERVATIONAL

Enrollment

112

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions

Prostate Cancer

Interventions

DEVICE

performance of PET/CT and whole-body MRI

For PET/CT radiopharmaceuticals, both registered in France:Fluoride (18F)FLUOROCHOLINE (18F)No contrast agent scheduled for MRI in the study RadiopharmaceuticalsSingle use, 2-4 MBq/kg body weight, IV infusion

Trial Locations (1)

75020

Service Médecine Nucléaire - Hôpital TENON, Paris

All Listed Sponsors

lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT01501630 - Role of PET/CT With Fluorine-18 Tracers of Bone Metastases in Prostate Cancer | Biotech Hunter | Biotech Hunter